I see your point and I feel your frustration. I am a significant share owner so I feel your pain. However, I am seeing Daxxify gaining significant traction in my practice and across my industry contacts. This supports my belief that the company has done enough to course correct and that patient investors will be rewarded sooner rather than later. I don't pay much attention to the first 12 months of a commercial launch. The numbers that will matter most to me is Q2 2024 vs Q2 2023 year over year growth comps and each quarter after that out to mid 2025. Over 10 years of drug development and $1B spent and I suspect we are a 18 to 24 months away from knowing if this will be a blockbuster drug for Revance.
News 
Market Data 
Discover 
